Artificial urinary sphincter longevity following transurethral resection of the prostate in the setting of prostate cancer.

In the SEER-Medicare population, AUS after cTURP remains rare. While there is an increased risk of infectious complications, AUS after cTURP fared similarly to AUS after RP in terms of device longevity. A history of radiation therapy leads to worse outcome for all patients.